Drug Target ID is a participant in the upcoming EU Innovative Medicines Initiative-2 (IMI-2) project PRISM that will study the (genetic and other) etiology of social withdrawal and cognitive deficits as shared traits between AD, major depression and schizophrenia, and that will start in early 2016. From 1 August 2015 onwards and together with the SME …